Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects. However, its effects on 5-HT neuronal activity, as well as its impact on models of neuropathic pain are unknown.
Cannabis triggers a complex set of experiences in humans including euphoria, heightened sensitivity to external experience, and relaxation. The primary noneuphorizing and nonaddictive compound of cannabis, cannabidiol(CBD), has recently been shown to possess considerable therapeutic potential for treating a wide range of
disorders such as chronic pain, nausea, epilepsy, pychosis, and anxiety.
Read more Todays Practitioner web site